Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Nabaparna Bhattacharya

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Tumor,Microenvironment,Concept,With,Cancer,Cells,,T-cells,,Nanoparticles,,Cancer,Associated

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

The payment followed the first patient dosing in the KOMET-017 Phase 3 registrational study for ziftomenib, a novel oral menin inhibitor under development for acute myeloid leukemia (AML).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.